Research ArticleCancer

HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase

+ See all authors and affiliations

Science Translational Medicine  12 Jul 2017:
Vol. 9, Issue 398, eaal5272
DOI: 10.1126/scitranslmed.aal5272

Article Information

vol. 9 no. 398

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication December 5, 2016
  • Accepted for publication June 10, 2017

Author Information

  1. Abhishek A. Chakraborty1,
  2. Eijiro Nakamura1,*,
  3. Jun Qi1,
  4. Amanda Creech2,
  5. Jacob D. Jaffe2,
  6. Joshiawa Paulk1,
  7. Jesse S. Novak1,3,
  8. Kshithija Nagulapalli4,
  9. Samuel K. McBrayer1,
  10. Glenn S. Cowley2,
  11. Javier Pineda1,,
  12. Jiaxi Song1,3,
  13. Yaoyu E. Wang4,
  14. Steven A. Carr2,
  15. David E. Root2,
  16. Sabina Signoretti1,3,
  17. James E. Bradner1 and
  18. William G. Kaelin Jr1,2,5,6,
  1. 1Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02215, USA.
  2. 2Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
  3. 3Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA.
  4. 4Center for Cancer Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
  5. 5Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA.
  6. 6Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
  1. Corresponding author. Email: william_kaelin{at}dfci.harvard.edu
  • * Present address: DSK Project, Medical Innovation Center, Kyoto University Graduate School of Medicine, Kyoto 606-8397, Japan.

  • Present address: Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.

AltMetrics

Article usage

AbstractFullPDF
Jul 20173933326640